 |
|
|
|||||
Sun Pharma Advanced Research Company (SPARC) psoriasis drug, Vibozilimod (SCD-044), failed to meet primary endpoints in Phase 2 trials for psoriasis and atopic dermatitis. The company has decided to discontinue development of the drug. Separately, a surprise FDA inspection is underway at Sun Pharmas Halol manufacturing facility.
Category:
News and Media
The charity is moving to a new site so it can help more families in need with essential supplies.
Category:
News and Media
Cochin Shipyard shares: The stock has posted exceptional gains, surging nearly 737% in the past two years, 1,178% over three years, and 1,649% in five years. Cochin Shipyard now holds a market capitalisation of Rs 55,272 crore.
Category:
News and Media
All news |
||||||||||||||||||
|
||||||||||||||||||